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Abstract
Minimal residual disease (MRD) in acute myeloid leukaemia (AML) poses
a major challenge due to drug insensitivity and high risk of relapse. Intensi-
fication of chemotherapy and stem cell transplantation are often pivoted
on MRD status. Relapse rates are high even with the integration of first-
generation FMS-like tyrosine kinase 3 (FLT3) inhibitors in pre- and post-
transplant regimes and as maintenance in FLT3-mutated AML. Pre-clinical
progress is hampered by the lack of suitable modelling of residual disease
and post-therapy relapse. In the present study, we investigated the nature
of pro-survival signalling in primary residual tyrosine kinase inhibitor
(TKI)-treated AML cells adherent to stroma and further determined their
drug sensitivity in order to inform rational future therapy combinations.
Using a primary human leukaemia-human stroma model to mimic the
cell–cell interactions occurring in patients, the ability of several TKIs in
clinical use, to abrogate stroma-driven leukaemic signalling was deter-
mined, and a synergistic combination with a mitogen-activated protein
kinase (MEK) inhibitor identified for potential therapeutic application in
the MRD setting. The findings reveal a common mechanism of stroma-me-
diated resistance that may be independent of mutational status but can be
targeted through rational drug design, to eradicate MRD and reduce treat-
ment-related toxicity.
Keywords: acute myeloid leukaemia, tyrosine kinase inhibitors, drug resis-
tance, microenvironment, minimal residual disease.
The FMS-like tyrosine kinase-3 internal tandem duplication
(FLT3-ITD) mutation confers a poor prognosis in acute
myeloid leukaemia (AML) due to a high relapse rate, and is
a major therapeutic target.1,2 Tyrosine kinase inhibitors
(TKIs) are currently approved for FLT3-mutated AML.3–5
Many clinical pathways now risk-stratify patients according
to whether minimal residual disease (MRD) is detectable or
not after initial chemotherapy and intensification of treat-
ment including stem cell transplantation (SCT) is pivoted on
MRD status. The bone marrow (BM) microenvironment is
implicated in drug resistance through activation of pro-sur-
vival signalling, stromal cytokine secretion and direct contact
of leukaemia cells at the stromal interface.6,7 The key focus is
now on identifying combination therapies with targeted
agents that can potentiate toxicity against AML in the con-
text of a cytoprotective microenvironment,8 in order to
achieve MRD-negative status at the earliest time-point and
before SCT, to reduce relapse risk and optimise patient out-
comes. Informing the rationale design of such therapies
requires an understanding of the signalling pathways acti-
vated on adherence of AML cells to stroma and its functional
consequences. Recent studies have reported efficacy of TKI
and azacytidine combinations to eliminate stromal protection
of blasts9; however, the signalling dependencies of niche
attached AML cells have not been characterised. Coupling
therapies able to specifically off-set stroma-dependent AML
signalling may help to eliminate MRD and reduce treatment-
related toxicity.
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Signalling through the FLT3 receptor can activate many
pathways including: phosphatidylinositol 3-kinase (PI3K)/
phosphatase and tensin homologue (PTEN)/protein kinase B
(Akt)/mammalian target of rapamycin (mTOR), Ras/Raf/mi-
togen-activated protein kinase (MEK)/extracellular signal-reg-
ulated kinase (ERK), and Janus kinase/signal transducers and
activators of transcription (JAK/STAT)10,11; however, the sig-
nalling profiles of stroma-adherent AML cells may differ
from non-adherent blasts. FLT3-ITD has been implicated in
regulating leukaemia cell adhesion through a4b1 integrin,12
but the reliance of TKI-resistant cells on stromal contact for
survival is unknown. High throughput screening of TKIs
using stroma-conditioned media suggests that synergy
between JAK2 and FLT3 inhibitors may override the secre-
tory stromal protection of FLT3-mutant AML.13 It is already
established that pacritinib, a dual FLT3/JAK2 inhibitor, can
inhibit FLT3-ITD AML growth in xenografts, and interest-
ingly, reduces intra-pulmonary leukaemic deposits in these
models, suggesting that it may mitigate the ability of AML
cells to seed onto extramedullary sites.14 Given that leukae-
mic cell lines may not have a dependency on stromal contact
for their survival, we investigated the oncogenic signalling
pathways active in both stroma-adherent and non-contact
primary AML cells that may contribute to drug-resistant
MRD in a TKI context. The ability of several TKIs, including
pacritinib, to kill primary AML cells was examined, in a sys-
tem that models primary AML–stromal interactions and
residual disease, thus providing clinically relevant therapeutic
insight.
Materials and methods
Cell lines and reagents
Pacritinib was supplied by CTI Biopharma Corp. (Seattle,
USA). PD0325901 was purchased from Sigma-Aldrich (St.
Louis, MO, USA). Cytosine arabinoside (Ara-C) was sup-
plied by the University Hospital of Wales pharmacy. Pona-
tinib was supplied by Ariad Pharmaceuticals (Cambridge,
MA, USA) and crenolanib by AROG pharmaceuticals (Dal-
las, TX, USA). Ruxolitinib was purchased from Cell Guid-
ance Systems Ltd (Babraham Bioscience Campus,
Cambridge, UK). MS-5 and MV4;11 cells (DSMZ-German
Collection of Microorganisms and Cell Cultures GmbH,
Braunschweig, Germany) were cultured in a-minimum
essential medium (MEM) (Sigma-Aldrich) and Iscove’s
modified Dulbecco’s media (IMDM), respectively, supple-
mented with 10% v/v fetal calf serum (FCS), 200 mmol/l
glutamine (Sigma-Aldrich) and 20 µg/ml gentamycin. HS5
cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM)-high glucose (Sigma-Aldrich), 10% FCS, 1% Glu-
tamax (Gibco by Life Technologies, Carlsbad, CA, USA)
and 20 µg/ml gentamycin. Stromal cells were not used
beyond passage 4.
Primary samples
Primary AML peripheral blood and BM samples were
obtained from patients with de novo AML at diagnosis
(Table 1) following written informed consent and in accor-
dance with the National Cancer Research Institute (NCRI)
AML trial bank regulations and the Declaration of Helsinki.
Mononuclear cells were separated by Ficoll-Hypaque density
gradient centrifugation. Primary cells (>75% viability) were
cultured in IMDM with 10% FCS, 200 mmol/l glutamine
(Sigma-Aldrich) and 20 µg/ml gentamycin for short-term
assays. Primary mesenchymal stromal cells (MSCs) from
healthy subjects or patients with AML at diagnosis were cul-
tured in a-MEM, 15% fetal bovine serum (FBS), 1% L-glu-
tamine (Gibco by Life Technologies) and 20 µg/ml
gentamycin. Normal BM (NBM)- and AML-derived MSCs
were used at passage 3 for assays. Multi-lineage potential of
MSCs was verified as described in Ref. [15].
Cytotoxic drug response and synergy assays
Primary AML blasts were seeded at a density of 1 9 106/ml
in 96-well plates and Cell Titer Glo assays set up according
to manufacturer’s instructions (Methods S1).
Annexin V apoptosis assay
Primary AML cells were seeded in triplicate for 24, 48, 72 h and
7 days in IMDM/10% FCS in the presence of pacritinib concen-
trations up to 1 µmol/l. Cells were stained with propidium
iodide (PI) for cell cycle status or Annexin V/PI for apoptosis
(Bender Medsystems Inc., Burlingame, CA, USA) and analysed
by flow cytometry for late apoptotic (annexin V+/PI+) fractions.
Intracellular flow cytometry
Primary AML cells were co-cultured with stroma for 3 h,
pacritinib or dimethyl sulphoxide (DMSO, vehicle control)
was added and further incubation maintained for 18 h.
Floating AML cells were removed and adherent AML cells
isolated by trypsinization. Cells were fixed and permeabilised
in Phosflow Perm II/III buffer according to the manufac-
turer’s instructions (BD Biosciences, San Jose, CA, USA).
CD45 distinguished AML and stromal populations. Co-stain-
ing with Vybrant (Thermo Fisher Scientific, Inc., Waltham,
MA, USA) cell viability dye excluded dead cells prior to anal-
ysis on the Accuri flow cytometer (BD Biosciences).
Leukaemic outgrowth assays
Primary AML cells were seeded on 80% confluent HS5. AML
cells were cultured in long-term culture-initiating cell (LTC-
IC) assay media [a-MEM, 125% heat-inactivated v/v FCS,
125% v/v heat-inactivated horse serum (Labtech International
Ltd, Heathfield, East Sussex, UK), 20 µg/ml gentamycin,
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Table 1. Patients’ characteristics and EC50 (pacritinib)
Characteristic Number
EC50, nmol/l,
median (range)
P (relation between
EC50 and characteristic)
All data 63 112 (11–12 400)
Age, years
0–29 10 99 (25–779) s
30–39 6 90 (19–361)
40–49 16 935 (11–732)
50–59 20 1915 (16–2600)
60+ 11 645 (13–12 400)
Median (range) 47 (0–70) 04†
Sex
Male 31 127 (11–1100)
Female 32 1095 (116–12 400) 06*
WBC count, 9109/l
0–99 2 Values: 415, 700
10–499 24 121 (22–779)
50–999 18 1235 (13–12 400)
100+ 19 56 (11–732)
Median (range) 614 (18–3865) 0005†
Type of AML
De novo 58 1135 (11–12 400)
Secondary 5 111 (20–380) 06*
Cytogenetic group†
Favourable 9 133 (20–1100)
Intermediate 43 111 (116–12 400)
Adverse 3 732 (361–779)
Unknown 8 965 (11–2600) 03†
FLT3 status
ITD wt 40 147 (19–2600)
ITD mutant 23 85 (11–12 400) 001*
ITD allelic ratio
ITD WT 40 147 (19–2600)
ITD mutant <50% 13 109 (116–12 400)
ITD mutant ≥50% 5 46 (28–11 530) 003†
ITD mutant ratio unknown 5
TKD WT 51 108 (11–12 400)
TKD mutant 12 138 (24–1100) 03*
NPM1 status
WT 41 115 (116–12 400)
Mutant 22 1105 (11–2600) 06*
ITD/NPM1 status
ITD wt/NPM1 wt 30 1725 (19–1100)
ITD wt/NPM1 mut 10 121 (43–2600)
ITD mut/NPM1 wt 11 56 (116–12 400)
ITD mut/NPM mut 12 905 (11–222) 009*
NRas status
NRas wt 51 147 (11–12 400)
NRas mutant 12 100 (11–322) 04
Runx1 status
Runx1 wt 55 100 (11–12 400)
Runx1 mutant 8 361 (97–732) 001*
CEBPa status
CEBPa wt 56 115 (11–12 400)
CEBPa mutant 7 40 (19–176) 002*
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200 mmol/l L-glutamine, 572 µmol/l b-mercaptoethanol (Life
Technologies, Gaithersburg, MD, USA), 1 µmol/l hydrocorti-
sone (Sigma-Aldrich), 20 ng/ml interleukin 3 (IL-3), 20 ng/ml
granulocyte-colony stimulating factor (G-CSF), 20 ng/ml
thrombopoietin (TPO; PeproTech Inc., London, UK)] with
drug or DMSO. Control plates were set up without stromal
monolayers. Cells were incubated for 7 days with drugs, and
cell viability tracked by Trypan blue (Sigma-Aldrich). After
suspension cell removal and drug washout, re-population from
residual stroma-adherent blasts was monitored over 7 days.
CD45-allophycocyanin (APC) was used to mark AML cells and
CD90-phycoerthyrin (PE) to distinguish stromal cells.
Genotyping for FLT3-ITD, tyrosine kinase domain
(TKD) and nucleophosmin 1 (NPM1)
See Methods S1.
Aldehyde dehydrogenase (ALDH) staining, LTC-IC and
secondary limiting dilution analysis (LDA) assays
Primary AML cells were stained for ALDH with Aldefluor
according to the manufacturer’s instructions (Stem Cell Tech-
nologies UK, Cambridge, UK), co-labelled for leukaemia stem
cell (LSC) populations with CD34 and CD38, and CD34+
CD38ALDHint populations cell sorted (BD Aria flow cell
sorter; BD Biosciences, San Jose, CA, USA) onto HS5 stroma
in 96-well plates for LTC LDA assays. Cultures were replen-
ished with fresh media and drugs or vehicle control on a bi-
weekly basis and maintained for 5 weeks. H4435 methylcellu-
lose was added after 5 weeks (Stem Cell Technologies) and
colonies scored after 2 weeks. Secondary colony-forming unit
(CFU) read-out was performed as described in Ref. [16]. LTC-
IC frequency was calculated using the on-line ELDA software
package (http://bioinf.wehi.edu.au/software/elda/).
Antibodies and Western blot analysis (WB)
See Methods S1.
In vivo experiments
All the experimental procedures were approved by Cardiff
University Animal Welfare and Ethical Review Body and
conform to the UK Home Office regulations. We established
humanised models of leukaemia in sub-lethally irradiated
adult (aged 7–10 weeks) NOD/SCID/IL2R/ mice (NSG,
one dose 200 cGy) by intravenous transplantation of 105
MV4;11 cells. At 14 days after the transplantation, mice were
split into two equal groups and given intraperitoneal injec-
tions of vehicle or pacritinib:PD0325901 (06:30 mg/kg
respectively) daily for 8 days. Mice were continually moni-
tored for symptoms of leukaemia and tumour load was
assessed at 6 weeks after inoculation. BM harvests were anal-
ysed by fluorescence-activated cell sorting (FACS), with
engraftment of human donor cells defined as hCD45 posi-
tive.
Statistical analysis
Significant differences between AML cell populations were
determined using a two-tailed paired t-test or a Mann–Whit-
ney U-test in GraphPad Prism (GraphPad Software Inc., San
Diego, CA, USA). The relationships between patient charac-
teristics and pacritinib half maximal effective concentration
(EC50) were determined using Wilcoxon rank-sum/Kruskal–
Wallis test for difference between groups and Spearman cor-
relation coefficient for continuous data ordered groups
(Table 1).
Results
Human stroma modulates the TKI sensitivity of primary
AML cells
Both pacritinib and ponatinib showed significantly greater
sensitivity than crenolanib on primary AML blasts (Fig 1A).
Second-generation FLT3 inhibitors showed good efficacy in
both wild-type (WT) and FLT3 mutants (Table 1) and
(Fig 1C,D). Pacritinib sensitivity was significantly greater in
the 23 patients with a FLT3-ITD (Fig. 1B), although a sensi-
tive WT group could be identified, suggesting a FLT3 muta-
tion-independent effect. As our interest was in the stroma-
mediated effects of TKIs, we focussed on its activity in our
primary models. For FLT3 independent effects of pacritinib,
drug efficacy in sensitive FLT3 WT patient samples was com-
pared to ruxolitinib, a JAK1/JAK2 inhibitor. Ruxolitinib
Table 1. (Continued)
Characteristic Number
EC50, nmol/l,
median (range)
P (relation between
EC50 and characteristic)
WT1 status
WT1 wt 54 111 (11–2600) 001*
WT1 mut 9 732 (60–12 400)
CEBPa, CCAAT/enhancer-binding protein alpha; ITD, internal tandem duplication; NPM1, nucleophosmin 1; TKD, tyrosine kinase domain;
WBC, white blood cells; WT1, Wilms tumour 1.
*Wilcoxon rank-sum/Kruskal test for difference between groups.
†Spearman correlation coefficient for continuous data/ordered groups.
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EC50s were significantly >1000 nmol/l for all samples except
for one AML, noted to have higher pJAK2 levels (Fig-
ure S1A,B). There were no JAK2 mutations detected in any
of the FLT3-WT or FLT3-mutant samples, suggesting pacri-
tinib sensitivity in this subset to be independent of JAK2 or
FLT3-ITD mutation status.
The presence of stroma reduced the response to TKIs by
increasing EC50 (Fig 1C,E,F) and reducing apoptosis of AML
cells. Pacritinib did not produce any significant toxicity to
stroma (Figure S3A,B). The induction of pro-survival sig-
nalling was greater in human:human co-cultures (Figure S3C)
and therefore HS5 was chosen for longer term co-culture
assays.
Pro-survival signals in primary AML cells are up-
regulated by contact with human stroma and are
differentially attenuated by TKIs
MSCs can support human haematopoietic stem cells
(HSCs)17 and maintain leukaemia-initiating cells (LICs) in
AML.18 Two populations of cells can be recognised in co-cul-
ture: (i) non-adherent AML cells exposed to stroma secreted
cytokines and (ii) AML cells adherent to stroma requiring
trypsinization for detachment. The latter population is of
interest because of direct leukaemia–stroma contact, which
may activate pro-survival signalling, promote drug resis-
tance19 and in LSC populations contribute to relapse.6 We
observed significant activation of phosphorylated STAT5
(pSTAT5) and pERK1/2 in both suspension and adherent
AML cells (Fig 2A, P < 0·05), confirmed by WB analysis
(Fig 2B). Contact of AML blasts with HS5 produced the
greatest increase in pERK, whilst pJAK2 signalling was not
induced. Pacritinib treatment suppressed pERK and pSTAT5
in all fractions more potently than crenolanib and ponatinib,
but higher drug concentrations were required in co-culture
(Fig 2B,D,E, P < 005; Figure S2A).
Wnt/-b-catenin signalling is frequently activated in FLT3-
ITD AML and has been implicated in microenvironmental
mediated leukaemogenesis.20 Active b-catenin significantly
increased on adherence of FLT3-ITD AML cells to stroma
(seven of 10 samples), and was sustained at 24 h (Fig 2A,
P < 005). This was adherence dependant, greater with HS5
and not increased in suspension AML cells, indicating a
requirement for direct stromal cell contact. On primary
AML-derived MSCs, a similar significant increase was
observed that was not present with cultures of NBM-
derived MSCs (P < 001). Pacritinib reduced active b-cate-
nin levels in a dose-dependent manner (P < 001, Fig 2C).
Ruxolitinib did not show any significant attenuation of
pERK, pSTAT, active b-catenin or pJAK2, confirming lack
of efficacy in AML and indicating stromal alterations of
pro-survival pathways by pacritinib to be independent of
JAK2 (Figure S2D).
The MEK inhibitor PD0325901 can synergise with
pacritinib to counteract stroma induced pERK feedback
Given the high induction and sustained expression of pERK
in co-culture assays, we assessed the synergy of pacritinib
with the MEK inhibitor, PD0325901, to counteract stromal
up-regulation of this pathway. Dose–response curves for
single and combination treated AML cells revealed synergy
in ITD and WT primary AML samples across a range of
drug effects at an optimum ratio of 5:1 (pacritinib:
PD0325901) (Fig 3A,B), with a median (range) combination
index (CI) value of 025 (0007–19) (n = 26). Pacritinib:
Ara-C had a limited synergistic effect with a modest CI
value of 063 at a ratio of 1:100 (Fig 3A), which could not
be improved with further dose ratios (data not shown).
Pacritinib/PD0325901 treatment produced significantly
greater pSTAT5 and pERK attenuation compared to single
agents in co-culture conditions (Fig 3C,D), suggesting speci-
ficity of ERK targeting and a potential role of MEK inhibi-
tors, to counter TKI-induced MEK feedback. B-cell
lymphoma 2 (Bcl-2) was significantly reduced with the
combination (Fig 3E) and greater apoptosis seen (Fig-
ure S4).
Dual therapy with pacritinib and the MEK inhibitor
PD0325901 reduces leukaemic outgrowth of stroma-
adherent cells and suppresses LIC in vitro and in vivo
Stromal outgrowth assays were set up to monitor ‘re-popula-
tion’ of the flask from residual adherent AML cells (Fig 4A–
C). Pacritinib was more effective than ruxolitinib in reducing
adherent cells and their outgrowth, an effect augmented by
the MEK inhibitor PD0325901 (Fig 4D). WT FLT3 AML also
showed some sensitivity, suggesting this combination can
effectively target both WT and FLT3-mutant AML cells on
stroma (Fig 4E,F).
Secondary CFU are considered a surrogate for in vivo drug
efficacy and to assess drug effects on residual disease not
modelled through xenograft studies. Residual drug-treated
colonies are re-plated for secondary CFU. Pacritinib:
PD0325901 combination therapy reduced CFU in AML com-
pared to NBM CD34+s, indicating a potential therapeutic
window for use. In contrast, ruxolitinib treatment showed
significant toxicity to NBM (Fig 5A).
Pacritinib treatment of CD34+CD38ALDHint AML
FLT3-ITD cells, known to have leukaemic reconstitution
potential and to predict relapse in patients,21 markedly inhib-
ited the ability of CD34+CD38ALDHint AML cells to form
cobblestone areas at 5 weeks on HS5 stroma and significantly
reduced LTC-IC frequency (Fig 5B, n = 6; P < 001 at
1 µmol/l pacritinib; Figure S6). Similar results were seen in
MS5 co-cultures (data not shown). There were no cobble-
stones with combination treatment.
Targeting drug resistance in AML
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Discussion
Modification of microenvironment-mediated drug resistance
is an important therapeutic strategy to sensitise niche pro-
tected AML cells to current agents and to combat MRD.
Relapse from FLT3-ITD disease is frequent and aggressive,
and as stromal cells can protect FLT3-ITD progenitors from
FLT3 inhibitors22,23 strategies modifying stroma-based AML
Figure 1. In vitro sensitivity of primary AML cells to potent FLT3 inhibition is suppressed in co-culture. (A) Primary AML sample efficacy assess-
ment with pacritinib, ponatinib and crenolanib. EC50 values determined through cell titre glo readout of dose–response curves over 10 doses
(n = 63 AMLs). Mean EC50 pacritinib 1916 nmol/l  217, ponatanib mean EC50 253.8 nmol/l  218, crenolanib mean EC50 5588 nmol/
l  5193 (*P < 0001). (B) Efficacy of pacritinib, PD0325 and standard therapeutic agent Ara-C. Pacritinib efficacy sub-divided according to
FLT3-mutation status. Mean EC50 ITD = 923 nmol/l versus WT 2294 nmol/l, (*P < 001, Mann–Whitney U-test [MWU]). (C) Comparison of
EC50 values at 48 h on co-culture (*P < 001, pacritinib n = 15 AMLs, ponatinib n = 6 AMLs, crenolanib n = 6 AMLs). (D) Primary samples
stained for apoptotic induction with Annexin V and propidium iodide (PI) after pacritinib treatment (n = 7, *P < 004, **P < 001 MWU).
Pacritinib treatment of FLT3-ITD cells induced a dose-dependent increase in apoptosis in Annexin V/PI assays (P < 005 at 300 nmol/I, P < 001
at ≥500 nmol/l at 72 h) with concomitant induction of cleaved caspase-3. (E) Dose-response analysis of pacritinib sensitivity in short-term 48 h
stromal co-cultures with HS5 stromal layers (n = 15 ITD-mutant AML samples, P < 003 MWU). (F) Annexin V and PI apoptotic fractions at
specified pacritinib doses +/ HS5 stromal culture (n = 8 primary AMLs, *P < 005, **P < 001 MWU).
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cytoprotection may enhance the efficacy of chemotherapy. This
is particularly important as FLT3 inhibitors are currently used
in intensive chemotherapy schedules and peri-transplantation.
In the present study, we investigated the ability of several
TKIs, including the potent JAK2/FLT3 inhibitor pacritinib,
to target stroma-adherent primary AML cells. This
Figure 2. HS5 and AML-derived stroma drive maximal pro-AML effects. (A) Intracellular flow cytometry comparing MS5 and HS5 co-culture
induction of AML survival signalling in suspension and adherent co-culture fractions. Comparison of active catenin induction in suspension and
adherent fractions on HS5, AML-derived MSCs (n = 4) and NBM-derived MSCs (n = 3). (B) Representative Western blot of AML alone and
stromal co-cultured AML blasts after 24 h with increasing doses of pacritinib (n = 4 AMLs blotted). (C) Reduction in active catenin intracellular
flow levels after pacritinib drug treatment at 3 h (*P < 005, **P < 001, n = 4). Flow cytometry mean fluorescence of (D) pSTAT5 and (E)
pERK1/2 in AML cell populations treated with pacritinib for 3 h compared to vehicle controls (*P < 005, n = 10).
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compound can suppress up-regulation of JAK2 in FLT3-in-
hibitor-resistant cells and reduce intrapulmonary leukaemia
deposits in mice. It has demonstrated activity in a phase I
trial in combination with cytarabine in FLT3-mutant AML24;
however, its effects on stroma-adherent cells, which may
drive relapse, has not been investigated. In the present study,
Figure 3. Combination treatment with pacritinib and the MEK inhibitor PD0325901. Primary FLT3-ITD AML samples were treated singly and
in combination with pacritinib and Ara-C or the MEK inhibitor PD0325901 for 48 h. (A) Scatter graph of combination index (CI) values for pri-
mary AML cells treated with pacritinib and PD0325901 (fixed ratio 5:1, n = 26) compared to pacritinib and Ara-C (fixed ratio 1:100, n = 29),
(median CI = 063 (+/) for pacritinib:Ara-C, median CI = 025 (+/) for pacritinib:PD0325901). (B) Example Isobologram analyses showing
fraction affected at each CI of pacritinib: PD0325901 at a 5:1 fixed ratio. (C) Representative Western blot of synergistic knockdown of pSTAT5
and pERK1/2 in pacritinib and PD0325901 combination treated AML blasts (representative of three primary AMLs). (D) Flow cytometric analysis
of pERK knockdown and (E) Bcl-2 reduction in single and co-culture assays at 48 h. Combination therapy produces significantly greater knock-
down of target than single agent alone. (n = 7 primary AML, P < 001 MWU).
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longer-term treatment with pacritinib reduced proliferation
of non-adherent AML and adherent AML cells and sup-
pressed re-growth of adherent leukaemia at clinically achiev-
able drug doses (2 µmol/l, maximum clinical equivalent
concentration). Pacritinib did not alter allelic ratios in resid-
ual stroma-adherent fractions and we surmise that adherent
cells may have less dependency on FLT3-mutation status
given the up-regulation of other pro-survival pathways
Figure 4. Dual FLT3/MEK targeting suppresses leukaemic out-growth of primary stroma-adherent AML cells. (A) Leukaemic blast growth in sus-
pension fraction of HS5 co-culture over 7 days of single and combination agent treatment (n = 13, *P < 001). (B) Average co-culture adherent
cells determined using vibrant adhesion assay (*P < 001, **P < 0001). (C) Leukaemic blast outgrowth from adherent blast fraction on HS5 co-
culture following washout of 7 day single and combination agent treatment (n = 13, *P < 003, **P < 0001). (D) Relative cell counts in adherent
and suspension fractions at day 14 of leukaemic outgrowth assays (n = 13, *P < 001, **P < 0001 MWU). (E) Day 7 and (F) Day 14 adherent
cell growth between ITD (n = 8) and WT (n = 5) after drug treatment (*P < 001 compared to single agents, **P < 0001 MWU).
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observed. A subset of WT-adherent AML cells were also sen-
sitive, arguing for a common pathway of inhibition on
stroma-adherent populations, independent of mutational sta-
tus. As expected, ruxolitinib showed little efficacy on primary
AML cells cultured alone and no significant JAK2 activity in
co-culture. However, ruxolitinib was effective in reducing
suspension and adherent cells in leukaemic outgrowth assays,
suggesting some activity on stroma-mediated protection of
blasts. This is most likely due to non-specific drug effects at
this dose, which is borne out by the significant toxicity to
NBM colonies, limited efficacy on LTC-IC populations, and
suggests targeting JAK2 alone may not resolve relapse from
residual LTC-IC populations. In contrast, pacritinib showed
a much wider therapeutic window due to reduced BM
Figure 5. Dual FLT3/MEK targeting suppresses leukaemia-initiating cells in vitro and in vivo. (A) Histogram plot of CD34+CD38ALDHint frac-
tions seeded by limiting dilution LTC-IC assay on HS5 layers. LTC-IC frequency determined by L-Calc (STEM CELL) at 5 weeks (n = 7,
*P < 001,**P < 0001 MWU). (B) Effects of pacritinib, ruxolitinib and combination treatment on 2° re-plated colony growth in AML blasts on
HS5 stroma (black bars n = 4) and NBM (white bars n = 3) CD34+ cells (*P < 001, **P < 0001). (C) In vivo analysis of combination efficacy
on MV4;11 xenografts using 7 daily injections of fixed ratio pacritinib:PD0325901 (06:30 mg/kg respectively). Tumour load was assessed at
6 weeks after inoculation. Bone marrow harvests were analysed by FACS, with engraftment of human donor cells defined as hCD45+-positive
(*P < 005).
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toxicity even in combination with a MEK inhibitor that aug-
mented its anti-AML efficacy. This combination showed sig-
nificant suppression of leukaemic outgrowth on stroma, pro-
survival ERK signalling and increase in apoptosis, suggesting
benefit as maintenance therapy to prevent relapse. Kinase
profiling of pacritinib has shown suppression of inhibitory
cytokines, which may explain its reduced toxicity to normal
haematopoietic cells.25
Both pSTAT5 and pERK were augmented in adherent
AML cells consistent with reported ERK activation in stromal
co-culture.26 Pacritinib inhibited stroma-driven pSTAT5, but
higher doses (1 µmol/l) were required to inhibit pERK in
non-adherent cells. Residual pERK in adherent AML cells
may explain the stroma-related resistance to apoptosis. Pacri-
tinib and the MEK inhibitor, PD0325901, could be synergis-
tically combined at lower doses to completely inhibit pERK.
In contrast, there was no striking synergy between pacritinib
and Ara-C, and TKI/MEK inhibitor combinations may be
well placed following high-dose chemotherapy and in main-
tenance to suppress residual blasts with minimal toxicity to
NBM.
LTC-ICs were reduced with pacritinib suggesting potential
to inhibit disease recurrence. Griessinger et al.18 have shown
that engraftment potential can be maintained following
ex vivo culture of primary AML cells on stroma, enabling the
modelling of chemoresistance ex vivo. In addition,
CD34+CD38Lin AML cells may show co-activation of
pERK, pSTAT5 and b-catenin.27 Secondary CFU assays sup-
port the efficacy of pacritinib on LIC populations in both
mouse:human and in the human:human systems, the latter
which we have found to have significantly higher pro-sur-
vival stimulation than cross-species models. This finding was
replicated in our humanised NOD/SCID/IL2R/ xenograft
models confirming significant anti-leukaemic activity of the
pacritinib/MEK combination treatment on human AML cells
in vivo.
Wnt-b-catenin is essential for the survival of AML stem/
progenitor cells28,29 and is activated by FLT3-ITD through
glycogen synthase kinase-3b inactivation and catenin stabili-
sation.30 Active b-catenin was up-regulated in stroma-adher-
ent cells, suggesting a role in AML-stromal interaction
through direct binding, and of note integrin avb3 has been
implicated in modulating sensitivity to sorafenib.31 This
observation was absent in adhesion to NBM-derived MSCs,
suggesting a therapeutic window for the malignant versus
healthy BM niche.
Taken together, these data suggest that pro-survival sig-
nalling is up-regulated in AML cells adherent to stroma and
may account for residual disease detected following
chemotherapy. The efficacy of pacritinib and other TKIs may
be significantly enhanced by inhibition of stroma-driven ERK
and catenin signalling through combination with a MEK
inhibitor, providing a rationale strategy to reduce residual
LICs in a human stromal context and prevent relapse in
AML.
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*P < 0.01). (B) Cell cycle analysis using PI incorporation
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*P < 0.01 single to combination dose comparison. Cells were
harvested labelled for CD45 and autoMACs separated prior
to fixing.
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